Logo Image
News
Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Publications
All JournalsEditorial BoardFor AuthorsYear in Review
More
Events
Frontline ForumSatellite Sessions
CME/CE
Resources
Awareness MonthThe Bispecifics NetworkNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career Center

Subscribe

  • News
  • Watch
  • Conferences
  • Publications
  • Events
  • CME/CE
  • Resources
  • Career Center
  • Subscribe
  • Adverse Effects
  • Artificial Intelligence
  • Brain Cancer
  • Breast Cancer
    • HER2-Positive Breast Cancer
    • Triple-Negative Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Esophageal Cancer
    • Pancreatic Cancer
    • Gastric Cancer
    • Liver Cancer
  • Genitourinary Cancers
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Ovarian Cancer
    • Cervical Cancer
  • Head & Neck Cancer
  • Hematologic Oncology
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Myeloproliferative Neoplasms
  • Infection
    • Vaccines
  • Leukemia
  • Lung Cancer
    • Small Cell Lung Cancer (SCLC)
    • Non-Small Cell Lung Cancer (NSCLC)
  • Lymphoma
  • Neuroendocrine Tumors
  • Oncology
  • Pediatric Cancers
  • Psycho-Oncology
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Surgery
  • Thyroid Cancer
Spotlight -
Psycho-Oncology|
Artificial Intelligence|
Career Center|
Radiation Oncology|
Surgery
Advertisement

C.A. Stein, MD, PhD

Advertisement

Articles by C.A. Stein, MD, PhD

Metastatic Adrenocortical Carcinoma With a Prolonged Response to Mitotane

BySumanta K. Pal, MD,Benjamin Gartrell, MD,Carl A. Olsson, MD,C.A. Stein, MD, PhD
July 15th 2014

Adrenocortical carcinoma is a rare disease, with an annual incidence rate ranging from 0.5 to 2.0 cases per million individuals.

Advertisement

Latest Updated Articles

  • Metastatic Adrenocortical Carcinoma With a Prolonged Response to Mitotane
    Metastatic Adrenocortical Carcinoma With a Prolonged Response to Mitotane

    July 15th 2014



Advertisement
Advertisement

Trending on CancerNetwork

1

FDA Approves Pertuzumab Biosimilar in HER2+ Breast Cancer

2

FDA Provides CRL to Ivonescimab/Chemotherapy for Pretreated EGFR+ NSCLC

3

Matching Neoadjuvant Therapy to Tumor Genomics in High-Risk Prostate Cancer

4

Partnering With Local Hospitals to Manage CRS and ICANS From Bispecific Antibodies

5

Subsequent Therapy May Have Narrowed the Overall Survival Gap in LITESPARK-011

  • About
  • Advertise
  • CureToday.com
  • OncLive.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Editorial
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us